Bytul Mokaddesur Rahman

Bytul Mokaddesur Rahman

Auto-generated profile, based on publicly available information

Bytul Mokaddesur Rahman


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2024 in Journal of Pharmaceutical Innovation
Verified
Journal Article
Closed access
PDF file
IAIsrat Zerin Alam
Israt Zerin Alam
JSJakia Sultana
Jakia Sultana
Mohsin kaziMohsin kazi
Mohsin kazi
Mohammad UddinMohammad Uddin
Mohammad Uddin
BRBytul Mokaddesur Rahman
Bytul Mokaddesur Rahman

26 November 2023 in Heliyon
Verified
Journal Article
Open access
SPSubrata Paul
Subrata Paul
KAKaniz Fatema Asha
Kaniz Fatema Asha
IAIsrat Zerin Alam
Israt Zerin Alam
AAAshraf Ali
Ashraf Ali
EAElias Al-Mamun
Elias Al-Mamun
BRBytul Mokaddesur Rahman
Bytul Mokaddesur Rahman
The main goal of this research was to develop better tablet formulations by utilizing solid dispersions (SDs) and coprocessing excipients composite to achieve a better release rate of poor water-soluble gliclazide. The solvent evaporation method made SDs of gliclazide with different carriers carplex 67, carplex 80, and carplex FPS 500 (weight ratio, 1:1). The drug release patterns of the SDs were all evaluated and optimized. The SDs were illustrated by using scanning electron microscopy (SEM), differential scanning calorimetry (DSC), X-ray powder diffraction (PXRD), and Fourier transform infrared spectroscopy (FTIR). Tablet batches FGC-1 to 8 were made using gliclazide-carplex 67 solid dispersions (GC67-SDs) and the co-processed composite of excipients, namely starch-MCC-povidone (SMP) and lactose-MCC-povidone-sodium starch glycolate (LMPS), prepared with coprocessing technology. We evaluated these batches by conducting physicochemical tests and comparing them to the existing commercial brand. In a water medium, the release of gliclazide from SDs peaked within the first 30 min, showing a roughly 5∼6-fold increase compared to plain gliclazide. This quick dissolution rate may be due to the amorphization of the drug, which improved the specific surface area, and increased wettability caused by the hydrophilic properties of carplex particles. This has been confirmed through SEM, DSC, FTIR, and PXRD analysis. All FGC formulations had satisfactory pre-compression factor results, while the post-compression parameters indicated good mechanical strength and homogeneity across the blend. All produced tablets met the weight variation, friability, and disintegration time limit set by the compendia. Through in vitro drug release testing, it was discovered that all FGC tablet batches had consistent and nearly identical release results compared to SDs of gliclazide. However, the FGC-5 to 8 batches containing LMPS composites were determined to be the most effective formulations. In the first 30 min in a water medium, the percentage of drug generated from the FGC-8 tablets involving GC67-SDs and co-processed composite LMPS-4 is approximately 3.5 times higher than the average release of currently marketed products (MPs). After storing the selected FGC tablet batches for three months at 40 °C and 75 % RH, there were no noticeable alterations in the amount of drug and drug release profiles across the batches. Based on these findings, it appears that using the carplex silica-based SDs approach, along with gliclazide and co-processing excipients composite, could result in significant benefits compared to the current commercial brands. This approach could be effectively utilized to create solid dosage forms for drugs that have low solubility in water.

1 January 2025 in MOJ Public Health
Verified
Journal Article
Open access
PDF file
TTTasnuma Tabassum
Tasnuma Tabassum
AFAdeeba Jaheen Faruqui
Adeeba Jaheen Faruqui
SMSumiya Sharmin Mou
Sumiya Sharmin Mou
Nasiba Binte BaharNasiba Binte Bahar
Nasiba Binte Bahar
FZFatema Tuz Zohora
Fatema Tuz Zohora
EAElias Al-Mamun
Elias Al-Mamun
COVID-19 has been a public health crisis for quite a long time worldwide. Providing primary health care during this has proven to be quite difficult. Telemedicine played an imperative part in this by minimizing virus spread and utilizing the time of healthcare experts. This survey was designed to know about the prevalence of telemedicine during Covid-19 pandemic as well as its future prospect in Bangladesh. Four stakeholders were categorized for the study: common people, physicians, pharmaceutical professionals and regulatory body. Data was collected both via online and offline. Among the general people, 50.23% took health services through telemedicine service during the pandemic and 24.64% before the pandemic. Both general people (78.88%) and physicians (60%) expressed their satisfaction regarding the service. 93% pharmaceutical professionals also suggested that telemedicine should be implemented in all hospitals. Among the service takers 100% people were prescribed cold medicines. 58% of the respiratory issues were addressed through telemedicine. Physicians as well as regulatory authority considered raising awareness about telemedicine to be an important factor. Therefore, telemedicine should be utilized in several ways in our health sector. The post-Covid-19 era presents a unique opportunity for Bangladesh to harness the potential of telemedicine in addressing healthcare disparities and improving access to quality care. While challenges persist, strategic investments, technological innovation, and policy support can ensure that telemedicine becomes a cornerstone of a more equitable and efficient healthcare system in Bangladesh.